Core Viewpoint - AngioDynamics (ANGO) has experienced a significant downtrend, with a 15.9% decline over the past four weeks, but it is now in oversold territory, suggesting a potential turnaround due to analysts' positive earnings outlook [1][3]. Group 1: Stock Performance - ANGO's stock has declined 15.9% in the last four weeks, indicating strong selling pressure [1]. - The stock is currently in oversold territory, as indicated by an RSI reading of 24.7, suggesting that selling may be exhausting [3]. Group 2: Analyst Sentiment - There is strong consensus among sell-side analysts that ANGO will report better earnings than previously predicted, with a 0.8% increase in the consensus EPS estimate over the last 30 days [3]. - ANGO holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises [3].

AngioDynamics, Inc. (ANGO) reported an adjusted loss per share of 11 cents for first-quarter fiscal 2025, against the year-ago quarter’s adjusted loss per share of 12 cents. The metric was also narrower than the Zacks Consensus Estimate of 15 cents.On a pro-forma basis (excluding Dialysis and BioSentry businesses, the divested PICC, Midline, and tip location product portfolios, and discontinued RadioFrequency and Syntrax support catheter products), adjusted loss per share in first-quarter fiscal 2025 was 11 ...

Table of Content UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended August 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | --- | |--------------------------------------------------------------------------------------------| | For the transition period from to Commission file number 0-50761 | | AngioDyn ...

AngioDynamics, Inc. (ANGO) is well-poised for growth in the coming quarters, courtesy of its potential in NanoKnife System. The positive outlook for the stock is driven by NanoKnife's strong performance and successful geographic expansion. However, pricing pressure and macroeconomic factors are concerns.Shares of this Zacks Rank #1 (Strong Buy) company have lost 2.4% year to date against the industry's 8.3% growth. The S&P 500 Index has gained 20% in the said time frame.The company designs, manufactures and ...

Investors didn't like the medical technology company's fiscal 2025 Q1 update.Shares of AngioDynamics (ANGO -17.52%) were crashing 17.1% lower as of 10:43 a.m. ET on Thursday. The steep sell-off came after the medical technology company announced its fiscal 2025 first-quarter update.AngioDynamics reported fiscal Q1 net sales of $67.5 million, up 1.1% year over year. This result was a little lower than the average analysts' revenue estimate of $67.93 million.The company posted a net loss of $12.8 million, or ...

AngioDynamics, Inc. (NASDAQ:ANGO) Q1 2025 Earnings Conference Call October 3, 2024 8:00 AM ET Company Participants Jim Clemmer - President and Chief Executive Officer Steve Trowbridge - Executive Vice President and Chief Financial Officer Conference Call Participants John Young - Canaccord Genuity Yi Chen - H.C. Wainwright Operator Good morning and welcome to the AngioDynamics Fiscal Year 2025 First Quarter Earnings Call. At this time all participants are in listen-only mode. A question-and-answer session w ...

U.S. stocks were mostly lower, with the Dow Jones index falling around 300 points on Thursday.Shares of AngioDynamics, Inc. ANGO fell sharply during Thursday's session following first-quarter results.AngioDynamics posted first-quarter adjusted loss of 11 cents per share, compared to market estimates of a loss of 15 cents per share. The company's quarterly sales came in at $67.491 million versus expectations of $67.933 million.AngioDynamics shares dipped 15.6% to $6.45 on Thursday.Here are some other big sto ...

AngioDynamics (ANGO) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to loss of $0.12 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 26.67%. A quarter ago, it was expected that this medical device maker would post a loss of $0.20 per share when it actually produced a loss of $0.06, delivering a surprise of 70%.Over the last four quarters, the company has ...

| --- | --- | |------------------------------------------------------|-------| | | | | AngioDynamics | | | First Quarter Fiscal Year 2025 Earnings Presentation | | | October 3, 2024 | | | --- ...

AngioDynamics Reports Fiscal Year 2025 First Quarter Financial Results LATHAM, N.Y.--(BUSINESS WIRE)— Oct. 3, 2024-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced financial results for the first quarter of fiscal year 2025, which ended August 31, 2024. Fiscal Year 2025 First Quarter Highlights Quar ...